Faculty profile

Sharon Nofech-Mozes

ResearcherPhysical SciencesUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Sharon Nofech-Mozes

Researcher

Physical Sciences

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
29 publications in the last five years, latest in 2026.
Senior (last) author on 3 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2022.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

116

Publications

595

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Artificial Intelligence Dcis Digital Pathology Mammography

Latest papers

Evaluating HER2 Scoring Criteria in Endometrial Carcinoma: Gynecologic Versus Gastric Guidelines for Trastuzumab and Trastuzumab-Deruxtecan Selection.
Cancers · 2026 · first author
High-Risk Benign Breast Lesions: An Ontario Health (Cancer Care Ontario) Recommendations Report
Current Oncology · 2026
Machine learning-based prediction of luminal breast cancer subtypes using polarised light microscopy.
British journal of cancer · 2025

All 116 publications

Latest funding

Using AI to predict the presence of occult invasive carcinoma following diagnosis of DCIS on biopsy
CIHR · 2022 · Principal investigator
$887,400
Validation of a novel biomarker classifier that predicts radiation response following breast-conserving surgery for ductal carcinoma in situ (DCIS)
CIHR · 2022 · Co-investigator
$1,981,352
Prospective Evaluation of Breast-Conserving Surgery Alone in Low Risk Ductal Carcinoma in Situ Defined by a Molecular Expression Assay Combined with Clinico-Pathological Features
CIHR · 2020 · Co-investigator
$1,235,476

All 6 grants and awards

116 publications.

Evaluating HER2 Scoring Criteria in Endometrial Carcinoma: Gynecologic Versus Gastric Guidelines for Trastuzumab and Trastuzumab-Deruxtecan Selection.

Nofech-Mozes S, Olkhov-Mitsel E, Lu FI, Huang WY, Plotkin A

Cancers2026First author

DOI: 10.3390/cancers18122009 PMID: 42352541

High-Risk Benign Breast Lesions: An Ontario Health (Cancer Care Ontario) Recommendations Report

Eisen A, Bane A, Causer P, Cordeiro E, Fienberg S, Kornecki A, Kulkarni A, Hong NL, Mancuso T, Muradali D

Current Oncology2026

DOI: 10.3390/curroncol33020067

Machine learning-based prediction of luminal breast cancer subtypes using polarised light microscopy.

Tumanova K, Khorasani M, Nofech-Mozes S, Vitkin A

British journal of cancer2025

DOI: 10.1038/s41416-025-03150-x PMID: 41044174

Napsin-A Expression in Mesonephric and Mesonephric-like Adenocarcinomas: Implications for Distinction From Clear Cell Carcinoma.

Mirkovic J, Olkhov-Mitsel E, Nofech-Mozes S, Fadare O, McCluggage WG

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists2025

DOI: 10.1097/pgp.0000000000001118 PMID: 40377328

Generative and integrative modeling for transcriptomics with formalin fixed paraffin embedded material.

Mucaki EJ, Zhang W, Saha A, Trebinjac S, Nofech-Mozes S, Rakovitch E, Dumeaux V, Hallett MT

Journal of translational medicine2025

DOI: 10.1186/s12967-025-07031-y PMID: 41029822

Mutational landscape of pure ductal carcinoma in situ and associations with disease prognosis and response to radiotherapy.

Rizvi N, Mucaki EJ, Salmini EL, Zhang M, Trebinjac S, Hahn E, Paszat L, Nofech-Mozes S, Hallett MT, Rakovitch E, Dumeaux V

Breast cancer research : BCR2025

DOI: 10.1186/s13058-025-02080-z PMID: 40629431

Cystic neutrophilic granulomatous mastitis: sensitivity and specificity of 16s rRNA and Sanger sequencing for Corynebacterium spp.

Yang E, Kozak R, Nofech-Mozes S, Salvant E, Olkhov-Mitsel E, Slodkowska E, Plotkin A, Hanna W, Lu FI

Journal of clinical pathology2024

DOI: 10.1136/jcp-2022-208651 PMID: 36697218

Analytical Validation and Performance Evaluation of Amplicon-Based Next-Generation Sequencing Assays for Detecting ERBB2 and Other Gene Amplifications in Solid Tumors.

Olkhov-Mitsel E, Chan D, Craddock KJ, Lin A, Luk G, Goswami RS, Wang H, Plotkin A, Nofech-Mozes S, Hwang DM, Huang WY

Cancers2024

DOI: 10.3390/cancers16233927 PMID: 39682116

Molecular Expression Assays Improve the Prediction of Local and Invasive Local Recurrence After Breast-Conserving Surgery for Ductal Carcinoma In Situ.

Hahn E, Sutradhar R, Paszat L, Nguyen L, Rodin D, Nofech-Mozes S, Trebinjac S, Jerzak KJ, Fong C, Rakovitch E

Journal of clinical oncology : official journal of the American Society of Clinical Oncology2024

DOI: 10.1200/jco.23.02276 PMID: 38941575

3D CT Radiomic Analysis Improves Detection of Axillary Lymph Node Metastases Compared to Conventional Features in Patients With Locally Advanced Breast Cancer.

Barszczyk M, Singh N, Alikhassi A, Van Oirschot M, Kuling G, Kiss A, Gandhi S, Nofech-Mozes S, Look Hong N, Bilbily A, Martel A, Matsuura N, Curpen B

Journal of breast imaging2024

DOI: 10.1093/jbi/wbae022 PMID: 38752527

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2022

Subject: Prospective PhD student: Artificial Intelligence Dear Professor Nofech-Mozes, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Evaluating HER2 Scoring Criteria in Endometrial Carcinoma: Gynecologic Versus Gastric Guidelines for Trastuzumab and Trastuzumab-Deruxtecan Selection." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Using AI to predict the presence of occult invasive carcinoma following diagnosis of DCIS on biopsy" (2022), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Sharon Nofech-Mozes

Research

Latest papers

Latest funding

Evaluating HER2 Scoring Criteria in Endometrial Carcinoma: Gynecologic Versus Gastric Guidelines for Trastuzumab and Trastuzumab-Deruxtecan Selection.

High-Risk Benign Breast Lesions: An Ontario Health (Cancer Care Ontario) Recommendations Report

Machine learning-based prediction of luminal breast cancer subtypes using polarised light microscopy.

Napsin-A Expression in Mesonephric and Mesonephric-like Adenocarcinomas: Implications for Distinction From Clear Cell Carcinoma.

Generative and integrative modeling for transcriptomics with formalin fixed paraffin embedded material.

Mutational landscape of pure ductal carcinoma in situ and associations with disease prognosis and response to radiotherapy.

Cystic neutrophilic granulomatous mastitis: sensitivity and specificity of 16s rRNA and Sanger sequencing for Corynebacterium spp.

Analytical Validation and Performance Evaluation of Amplicon-Based Next-Generation Sequencing Assays for Detecting ERBB2 and Other Gene Amplifications in Solid Tumors.

Molecular Expression Assays Improve the Prediction of Local and Invasive Local Recurrence After Breast-Conserving Surgery for Ductal Carcinoma In Situ.

3D CT Radiomic Analysis Improves Detection of Axillary Lymph Node Metastases Compared to Conventional Features in Patients With Locally Advanced Breast Cancer.

Using AI to predict the presence of occult invasive carcinoma following diagnosis of DCIS on biopsy

Validation of a novel biomarker classifier that predicts radiation response following breast-conserving surgery for ductal carcinoma in situ (DCIS)

Prospective Evaluation of Breast-Conserving Surgery Alone in Low Risk Ductal Carcinoma in Situ Defined by a Molecular Expression Assay Combined with Clinico-Pathological Features

DCIS-Precise: A Genomics-Driven Model for Predicting DCIS Response to Radiation

The Canadian F.I.G.H.T. (Fluorescence Image-Guided Help in Treating) Breast Cancer Surgical Trial

The Canadian F.I.G.H.T. (Fluorescence Image-Guided Help in Treating) Breast Cancer Surgical Trial

Frequent collaborators

Eileen Rakovitch

Lawrence Paszat

Allan Covens

Rinku Sutradhar

Arun Seth

Anita Bane

Danielle Rodin

Nicole Look Hong

Vanessa Dumeaux

Zuzana Kos

Andrea Eisen

Iwa Kong

Maureen Trudeau

Andrea Eisen

Tulin Cil

Arjun Sahgal

Sunit Das

Bret Wehrli

Gang Wang

Nick Baniak

Vasily Giannakeas

Robert Kozak

Eldad Zacksenhaus

Muriel Brackstone

Anne Martel

Naomi Matsuura

Jean-Yves Masson

Sukhbinder Dhesy-Thind

Timothy Whelan

Jean-claude Cutz

Ameya Madhav Kulkarni